

32-1351: IGFBP5 Recombinant Protein

Alternative Name : IGFBP-5,IBP-5,IGF-binding protein 5.

Description

Source : Escherichia Coli. IGFBP5 Human Recombinant produced in E.Coli is a single, non-glycosylated, homodimeric polypeptide chain containing 252 amino acids and having a molecular mass of 28.6 kDa. IGFBP5 is purified by proprietary chromatographic techniques. IGFBP5 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Product Info

Amount :	25 µg
Purification :	Greater than 98.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.
Content :	IBP-5 was lyophilized from a concentrated (1mg/ml) solution containing 10mM sodium Citrate pH-3
Storage condition :	Lyophilized IBP5 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IGFBP 5 should be stored at 4°C between 2-7 days and for future use below -18°C.For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.
Amino Acid :	LGSFVHCEPC DEKALSMCPP SPLGCELVKE PGCGCCMTCA LAEGQSCGVY TERCAQGLRC LPRQDEEKPL HALLHGRGVC LNEKSYREQV KIERDSREHE EPTTSEMAEE TYSKIFRPK HTRISELKAE AVKKDRRKKL TQSKFVGGAE NTAHPRIISA PEMRQESEQG PCRRHMEASL QELKASPRMV PRAVYLPNCD RKGIFYKRKQC KPSRGRKRG I CWCVDKYGMK LPGMEYVDGD FQCHTFDSSN VE.

Application Note

It is recommended to reconstitute the lyophilized Insulin-Like Growth Factor Binding Protein-5 in sterile 18M Ω -cm H₂O not less than 100 Ω µg/ml, which can then be further diluted to other aqueous solutions. The ED₅₀, calculated by its ability to inhibit IGF-II induced proliferation of MCF-7. The expected ED₅₀ for this effect is < 0.4 Ω µg/ml, corresponding to a specific activity of > 2500 IU/mg in the presence of 15ng/ml of rHuIGF-II.

